Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Dezember 2025 09:15 ET | Quelle: Longeveron

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Week 2026.
01. Dezember 2025 12:00 ET | Quelle: Longeveron

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.
12. November 2025 09:05 ET | Quelle: Longeveron

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron issued US patent for method of treating aging-related frailty in patients with inflammaging using its proprietary stem cell therapy.
28. Mai 2024 08:05 ET | Quelle: Longeveron

Longeveron® to Attend BIO International Convention 2024

Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.